If you have been reading about Working solution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-16. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
== Ease of doing business == World Bank's Doing Business 2017; Equal Opportunity for All: Thailand ranked 46th (1-easiest; 190=difficult) of 190 nations in the "Ease of Doing Business" rankings. Other ASEAN states ranked: Singapore, 2; Malaysia, 23; Brunei, 72; Vietnam, 82; Indonesia, 91; Philippines, 99; Cambodia, 131; Laos, 139; Myanmar, 170. World Bank's Doing Business 2016: Measuring Regulatory Quality and Efficiency: Thailand ranked 49th overall of 189 nations (1=best, 189=worst) in ease of doing business, a drop of three places in the rankings since the 2014 survey prior to the May coup. Among ASEAN nations, Thailand ranked third behind Singapore and Malaysia. In detailed rankings, Thailand ranked 97th worldwide in getting credit, 96th in ease of starting a business, 70th in paying taxes, 39th in dealing with construction permits, 57th in registering property and enforcing contracts, 56th in trading across borders, 36th for protecting minority investors, and 49th in resolving insolvency.
The supply of parasympathetic nerves to the face and the upper jaw (maxilla) derives from the greater superficial petrosal (GSP) branch of cranial nerve VII, the facial nerve. The GSP nerve joins the deep petrosal nerve (of the sympathetic nervous system), derived from the carotid plexus, to form the vidian nerve (in the vidian canal) that traverses the pterygopalatine ganglion (an autonomic ganglion of the maxillary nerve), wherein only the parasympathetic nerves form synapses, which serve the lacrimal gland and the glands of the nose and of the palate, via the (upper jaw) maxillary division of cranial nerve V, the trigeminal nerve.
== History == Hohhot Baita Airport was opened on 1 October 1958. When it first opened to air traffic, it had only one dirt runway, three single‑story buildings, and five tents. The taxiway and apron were simple, and the runway measured 1,500 meters in length and 100 meters in width. In the mid-1980s and 1990s, it underwent two expansions and in June 2007 a new terminal was constructed. The new terminal covers an area of 54,499 square metres (586,620 sq ft) with 11 parking jetways and is capable of handling three million passengers each year. Its runway was also lengthened and its widened to accommodate jumbo jets such as the Airbus A380. It served as one of the diversion airports for air traffic during the 2008 Summer Olympics. With the rapid expansion of the city, Baita Airport is now surrounded by urban area and has no more room to expand to accommodate growing traffic. The Hohhot Shengle International Airport is being constructed in Horinger County which will replace Baita Airport and Baita is set to be closed once the new airport opened.
=== Trust in the institutions === In 2019, the Pew Research Center interviewed over 2,000 Americans aged 18 and over on their views of various components of the federal government. They found that 54% of the people between the ages of 18 and 29 wanted larger government compared to 43% who preferred smaller government and fewer services. Older people were more likely to pick the second option. 2018 polls conducted by the Pew Research Center found that 70% of Americans aged 13 to 17 wanted the government to play a more active role in solving their problems. A 2022 poll by Pew showed that overall, medical experts, the military, and scientists were among the most trusted groups in the United States. But while a majority of Americans believed it was important for their country to remain a global leader in science, people aged 18 to 29 were somewhat less inclined to think so compared to older cohorts and were slightly more optimistic about the standing of U.S. science on the international stage. However, Generation Z's trust in institutions or the nation itself has been declining. Polls conducted during the early 2020s showed that only a minority of Americans aged 18–29 thought that their country was heading in the right direction or agreed that democracy was the best form of government. About two thirds did not trust their government.
Sources: en.wikipedia.org
An ion source is a device that creates atomic and molecular ions. Ion sources are used to form ions for mass spectrometers, optical emission spectrometers, particle accelerators, ion implanters and ion engines.
== Research == Lasofoxifene is under development by Sermonix Pharmaceuticals for the treatment of metastatic breast cancer and dyspareunia associated with vaginal atrophy in the United States and Europe. It is also being researched for the potential treatment of ovarian cancer. As of December 2017, lasofoxifene is in phase III clinical trials for breast cancer and phase II clinical studies for dyspareunia.
frequent blood glucose monitoring (8–10 times daily); continuous blood glucose monitoring; logging and review of blood glucose values, searching for patterns of low blood sugar values; conservative increases in insulin delivery; awareness to the signs of hypoglycemia; awareness to hyperglycemia in response to increased delivery of insulin; use of appropriate types of insulin (long-acting, short-acting, etc.) in appropriate amounts.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}{\frac {\mathrm {d} N_{A}}{\mathrm {d} t}}&=-\left({\frac {\mathrm {d} N_{B}}{\mathrm {d} t}}+{\frac {\mathrm {d} N_{C}}{\mathrm {d} t}}\right)\\-\lambda N_{A}&=-N_{A}\left(\lambda _{B}+\lambda _{C}\right)\\\end{aligned}}}
=== Miscellaneous === Galactogogues such as the peripherally selective D2 receptor antagonist and prolactin releaser domperidone can be used to induce lactation in transgender women who wish to breastfeed. An extended period of combined estrogen and progestogen therapy is necessary to mature the lobuloalveolar tissue of the breasts before this can be successful. There are several published reports of lactation and/or breastfeeding in transgender women. The World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8), released in September 2022, recommends against therapeutic strategies including supraphysiological estradiol levels (>200 pg/mL), use of progesterone (including rectal progesterone), use of bicalutamide, and monitoring of the ratio of estrone to estradiol. This is due to lack of data to support these approaches in transfeminine people as well as potential risks. The WPATH SOC8 also recommends against the use of 5α-reductase inhibitors such as finasteride in transfeminine people.
== In France == Raymond arrived in Europe in 1922 and settled in Paris in 1927. He nonetheless retained links with the newly formed republic of Turkey, and prepared sketches for Turkey's projected participation in the 1925 International Exposition of Decorative Arts in Paris.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.